First patient dosed in Innovent wet AMD trial

Innovent Biologics has dosed the first patient in a phase 1 trial of IBI302, the company’s wet age-related macular degeneration treatment candidate, according to a press release.

A single intravitreal injection of IBI302, a recombinant fully human bispecific fusion protein targeting VEGF and complement proteins, will be evaluated in 36 patients with wet AMD in the open-label, single-center, dose escalation clinical trial.

“As the world’s first antibody-like bispecific fusion complement protein for ocular fundus diseases, IBI302 is designed to cure AMD by attacking its root causes in addition to relieving the symptoms,” Michael Yu, founder, CEO and chairman of Innovent, said in the release. “Hopefully, through our efforts, IBI302 can benefit AMD patients and their families.”

Innovent Biologics has dosed the first patient in a phase 1 trial of IBI302, the company’s wet age-related macular degeneration treatment candidate, according to a press release.

A single intravitreal injection of IBI302, a recombinant fully human bispecific fusion protein targeting VEGF and complement proteins, will be evaluated in 36 patients with wet AMD in the open-label, single-center, dose escalation clinical trial.

“As the world’s first antibody-like bispecific fusion complement protein for ocular fundus diseases, IBI302 is designed to cure AMD by attacking its root causes in addition to relieving the symptoms,” Michael Yu, founder, CEO and chairman of Innovent, said in the release. “Hopefully, through our efforts, IBI302 can benefit AMD patients and their families.”